JNJ - Johnson & Johnson
| Previous close | 130.78 |
| Open | 130.11 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's range | 129.33 - 130.75 |
| 52-week range | 121.00 - 148.99 |
| Volume | 4,498,079 |
| Avg. volume | 7,405,407 |
| Market cap | 341.878B |
| Beta (3Y monthly) | 0.73 |
| PE ratio (TTM) | 21.51 |
| EPS (TTM) | 6.02 |
| Earnings date | 15 Oct 2019 |
| Forward dividend & yield | 3.80 (2.91%) |
| Ex-dividend date | 2019-08-26 |
| 1y target est | 149.35 |
- Zacks
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
- Zacks
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
- Zacks
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
- Zacks
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $131.17, moving +1.25% from the previous trading session.
- Zacks
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
- Zacks
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
- Zacks
Theravance Announces Positive Early Data on JAK Inhibitor
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
- Zacks
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
- Zacks
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
- Simply Wall St.
An Intrinsic Calculation For Johnson & Johnson (NYSE:JNJ) Suggests It's 43% Undervalued
How far off is Johnson & Johnson (NYSE:JNJ) from its intrinsic value? Using the most recent financial data, we'll take...
- Motley Fool
Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August
The biopharma announced fiscal third-quarter 2019 operating results and multiple updates from the pipeline.
- Motley Fool
The 11 Biggest Dividend Stocks on the Market
Some of the biggest companies on earth are giving their investors a share of the profits each quarter through dividends.
- Zacks
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
- Zacks
Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
- Motley Fool
How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks?
Investors need to be careful about which pharmaceutical stocks they own.
- Zacks
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease
Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
- Zacks
J&J's Stelara Gets Approval in EU for Ulcerative Colitis
Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
- Zacks
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $128.86, marking a +0.09% move from the previous day.
- Motley Fool
Forget Coca-Cola: Here Are 2 Better Dividend Stocks
Coke's dividend is sweet, but these two stocks offer comparable yields and better long-term prospects.
- Motley Fool
What the Johnson & Johnson Opioid Ruling Means for the Cannabis Industry
The fine issued to the company last week was the first of its kind relating to the opioid crisis, and its effects could be far-reaching.
- Reuters
U.S. judge orders big drug companies to face opioid trial
U.S. District Judge Dan Polster, who oversees roughly 2,000 opioid lawsuits by states, counties and cities, said the plaintiffs can try to prove that drugmakers' deceptive marketing of the painkillers caused a harmful, massive increase in supply that pharmacies and distributors did not do enough to stop. "A factfinder could reasonably infer that these failures were a substantial factor in producing the alleged harm suffered by plaintiffs," the Cleveland-based judge wrote.
- Zacks
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
- Reuters
Bayer hires former J&J executive for more pharma deals
Bayer said it hired Johnson & Johnson executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline. De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival J&J, where she lead business development activities across different therapeutic areas and regions. Based in Berkeley, California, the Belgian national will have a more senior role than her predecessor, reporting directly to the head of pharmaceuticals, Stefan Oelrich, and taking a seat on the division's Executive Committee.
- Zacks
Allergan Settles Ahead of Multi-District Opioid Litigation
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.
